Latent Labs Emerges to Build Programmable De Novo Protein Design Foundation Models
November 14, 2026 • Source: FierceBiotech
Founded by former DeepMind AlphaFold2 co-lead Simon Kohl, Latent Labs announced its generative biology platform focused on zero-shot de novo protein binders and therapeutic enzymes.
**Executive Summary (2026-11-14):** Founded by former DeepMind AlphaFold2 co-lead Simon Kohl, Latent Labs announced its generative biology platform focused on zero-shot de novo protein binders and therapeutic enzymes. Source: FierceBiotech.
Technical Architecture & R&D Impact
The platform aims to eliminate iterative wet-lab affinity maturation by directly generating atomically accurate protein-protein interaction interfaces in silico.
Enterprise Biopharma Procurement Takeaways
For computational biology leads, medicinal chemists, and R&D IT architects, this milestone underscores the rapid convergence of wet-lab experimental validation and scalable cloud foundation models during H2 2026. Teams evaluating vendors in the Launch category should benchmark API reproducibility, GxP audit readiness, and zero-data-retention VPC deployment terms.
Related Products
Published November 14, 2026
More NewsLast updated: November 14, 2026
